You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
This finding has the potential to expand the current utility of the panel to identify an important subgroup of people who would benefit from less treatment, the firm said.
The firm's recent funding round will support its CLIA-certified laboratory that opened last year and the launch of its first RNA-based diagnostic test.
The firm's Cxbladder Monitor test was shown to have a high negative predictive value compared to other commercially available urine diagnostic tests for bladder cancer.
The firm recently announced that its nanoparticle tagging technology demonstrated higher sensitivity in detecting signs of disease than conventional methods.
The company's new blood-based test is the first clinical test offering that the company will be offering at its New York-based CLIA laboratory.
The company is in the beginning stages of product development, but is confident that it has a product that will be successful in the early diagnostics market.
The company recently closed a $7 million funding round and added to its executive team as it aims for a 2017 launch for its test.
The company has recently launched its first diagnostic test on the market and is developing a second, which is currently in clinical trials.